Clobetasol

DEA Class;  Rx

Common Brand Names; Cormax, Clobex, Clobex Spray, Cormax Ointment, Cormax Scalp Application, Impoyz, Olux, Olux-E, Clobex Shampoo, Clodan Kit, Clodan Shampoo

Indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

Indicated for moderate-to-severe forms of scalp psoriasis

Indicated for moderate to severe plaque psoriasis

For the treatment of corticosteroid-responsive dermatoses, including atopic dermatitis, localized vitiligo, eczema, phimosis, lichen planus, and localized bullous pemphigoid. For the general treatment of corticosteroid-responsive dermatoses. Topical dosage (cream, gel, foam, or ointment) Adults

For the treatment of atopic dermatitis. Topical dosage (cream, gel, foam, or ointment) Adults

For the treatment of psoriasis. Topical dosage (non-emollient cream, foam, gel, or ointment) Adults

For the treatment of vulvar lichen sclerosus. Topical dosage (cream) Adult females

For the alternative treatment of vision-threatening periocular capillary hemangioma in infancy and early childhood. Topical dosage (cream) Children and Infants

Viral, fungal, or tubercular skin lesions

Hypersensitivity

Ophthalmic use

Lotion

• Skin atrophy (4.2%)
• Telangiectasia (3.2%)
• Discomfort skin (1.3%)
• Dry skin (1%)

Frequency Not Defined

Skin atrophy

Striae

Burning

Cracking/fissuring of the skin

Erythema

Folliculitis

Irritation

Numbness

Pruritus

Stinging

Hypopigmentation (high potency topical steroids)

Intracranial hypertension reported in children with use of topical formulation

Adrenal suppression, Cushing syndrome, hyperglycemia

Acneform lesions

Secondary infection

Pigmentation changes

HPA suppression (with higher potency used >2 weeks); doses as low as 2 g/day can produce HPA suppression

Chronic topical corticosteroid therapy may interfere with growth and development in children

May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, especially in younger children or patients receiving high doses for prolonged periods

Use lower potency in children; may absorb proportionally larger amounts after topical application and may cause systemic effects; treatment of children <12 years not recommended; prolonged use may affect growth velocity (routinely monitor growth in pediatric patient); Clobex lotion, Clobex spray, Clobex shampoo, Clodan shampoo not recommended for use in patients <17 years

Allergic contact dermatitis reported with use; diagnosed by failure to heal rather than clinical exacerbation

Kaposi sarcoma reported with prolonged corticosteroid treatment; consider discontinuing therapy if it occurs

Percutaneous absorption of corticosteroids may cause manifestations of Cushing syndrome

Topical corticosteroids may increase the risks of glaucoma and posterior subcapsular cataract; glaucoma and cataracts reported in postmarketing; avoid contact with eyes; advise patients to report any visual symptoms

Foam dosage form is flammable; avoid fire, flame, or smoking during and immediately following application

Local effects, including perioral dermatitis, acneiform eruptions, folliculitis, hypopigmentation, skin atrophy, miliaria, secondary infection, and telangiectasia may occur; effects may be reversible

Concomitant skin infections may be present or develop during therapy; discontinue if dermatological infection persists after antimicrobial therapy

Pregnancy

Safety data on clobetasol in pregnant woman is not available

Lactation

No information is available regarding the presence of clobetasol in breast milk or its effects on the breastfed infant or on milk production

Adults

50 mL/week scalp or topical solutions and shampoo; 59 mL/week spray solution; 50 g/week other topicals.

Geriatric

50 mL/week scalp or topical solutions and shampoo; 59 mL/week spray solution; 50 g/week other topicals.

Adolescents

>= 16 years: Safety and efficacy of lotion, shampoo, and spray solution have not been established; 50 g/week of other formulations.
13 to < 16 years: Safety and efficacy of emollient cream, lotion, shampoo, and spray solution have not been established; 50 g/week of other formulations.

Children

>= 12 years: Safety and efficacy of emollient cream, lotion, shampoo, and spray solution have not been established; 50 g/week of other formulations.
< 12 years: Safety and efficacy have not been established.

Infants

Safety and efficacy have not been established.

Neonates

Safety and efficacy have not been established.

Clobetasol Propionate

cream, topical

• 0.025% (Impoyz)
• 0.05% (Temovate)

foam, topical

• 0.05% (Olux, Olux E)

gel, topical

• 0.05%

lotion, topical

• 0.05% (Clobex)

ointment, topical

• 0.05% (Temovate)

shampoo, topical

• 0.05% (Clobex Shampoo, Clodan Shampoo, Clodan Kit)

solution, topical

• 0.05%

spray, topical

• 0.05% (Clobex Spray)